Labcorp Reports 5.8% Revenue Growth to $3.731 Billion in Q2 2026

Labcorp Holdings Inc. reported a revenue increase of 5.8% for the second quarter of 2026, reaching $3.731 billion compared to $3.527 billion in the same period of 2025. The growth was attributed to organic revenue growth of 4.2%, acquisitions contributing 1.2%, and favorable foreign currency translation effects of 0.4%. For the first half of 2026, total revenues also rose by 5.8% to $7.269 billion, up from $6.872 billion in the prior year. The company's net earnings for the second quarter were $299.1 million, or $3.66 per share, compared to $238.3 million, or $2.85 per share, in the previous year.

In terms of operational performance, the Diagnostics Laboratories segment generated $2.901 billion in revenue for the second quarter, reflecting a 5.5% increase year-over-year, while the Biopharma Laboratory Services segment saw a 6.5% rise to $836.2 million. The increase in the Diagnostics segment was driven by a 3.6% organic revenue growth and a 1.9% contribution from acquisitions. The total volume of requisitions in the Diagnostics segment increased by 3.0%, with a price/mix increase of 2.5%. The Biopharma segment's growth was primarily due to organic growth of 6.2% and favorable foreign currency translation.

Labcorp's financial position showed a decrease in cash and cash equivalents, which fell to $141.8 million from $532.3 million at the end of 2025. The company reported total assets of $18.532 billion, up from $18.393 billion at the end of the previous fiscal year. The total liabilities increased to $9.909 billion from $9.756 billion, with long-term debt rising to $5.858 billion from $5.085 billion. The company also engaged in significant acquisitions, spending approximately $528.6 million on various businesses during the first half of 2026, which included a planned acquisition of an outreach laboratory services business for about $155 million expected to close in the third quarter.

The company’s operational efficiency is reflected in its cost of revenues, which increased by 5.6% to $2.619 billion, while the cost of revenues as a percentage of total revenues slightly decreased to 70.2% from 70.3%. Selling, general, and administrative expenses remained stable at $577.2 million, representing 15.5% of revenues, down from 16.4% in the previous year. The company also reported an increase in amortization of intangibles and other assets, which rose to $78.1 million from $68.3 million.

Looking ahead, Labcorp anticipates continued growth driven by its strategic acquisitions and operational efficiencies. The company remains focused on integrating its recent acquisitions and enhancing its service offerings. However, it also acknowledges potential challenges from regulatory changes and market conditions that could impact its revenue streams. The company expects to maintain compliance with its debt covenants and believes it has sufficient liquidity to meet its operational needs in the foreseeable future.